Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05445232 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
A Phase 1 study of Obesity, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT05445232: Completed Phase 1 study of Obesity, sponsored by Eli Lilly and Company.
NCT05445232 is a Phase 1 study of Obesity that has completed, run by Eli Lilly and Company. The registered enrollment target is 32 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05445232, a Phase 1 study of Obesity, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.
Primary Outcome
PK: AUC\[0-∞\] of Midazolam
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Caffeine
- DRUG Warfarin
- DRUG LY3437943
Study Locations (2)
Florida
- Covance Clinical Research Unit - Daytona Beach
Texas
- Covance Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-07-08 |
| Est. Completion | 2023-02-24 |
| Phase | Phase 1 |
What the finished NCT05445232 record still lists
NCT05445232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Midazolam is the first listed.
NCT05445232 reports a single indexed study location in Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05445232 about?
NCT05445232 is a clinical study titled "A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants". The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each ...
What is the current status of trial NCT05445232?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-07-08. Estimated completion is 2023-02-24.
What conditions does trial NCT05445232 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT05445232?
The interventions under investigation include: Midazolam (DRUG), Caffeine (DRUG), Warfarin (DRUG), LY3437943 (DRUG).
Who is sponsoring clinical trial NCT05445232?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05445232 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05445232's enrollment target sits among peer trials
32 839th of 1053 higher than 208 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI